Related Experiment Video
Updated: Aug 17, 2026

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
Published on: March 17, 2016
HES-1 inhibits 17beta-estradiol and heregulin-beta1-mediated upregulation of E2F-1
Johan Hartman1, Patrick Müller, James S Foster
1Center for Biotechnology, Department of BioSciences, Karolinska Institutet, Novum, S-141 57 Huddinge Sweden.
Abstract:
We have previously shown that expression of the transcription factor HES-1 is required for the growth-inhibitory effect of all-trans retinoic acid on MCF-7 cells. In this study, we have used T47D cells with tetracyclin-regulated expression of wild-type or a dominant-negative form of HES-1. Expression of HES-1 in T47D cells inhibited G1/S-phase transition and activation of Cdk2 elicited by estrogen. Estrogen treatment of T47D cells caused increased expression of E2F-1, and this expression was inhibited by cotreatment with all-trans retinoic acid. We show that the effect is mediated through HES-1, which directly downregulates E2F-1 expression through a CACGAG-site within the E2F-1 promoter. Furthermore, proliferation caused by heregulin-beta1 treatment of T47D cells was inhibited by all-trans retinoic acid and this effect was mediated by HES-1. Interestingly, heregulin-beta1-mediated upregulation of E2F-1 expression was directly inhibited by HES-1 through the same CACGAG-site as seen with estrogen-stimulated induction. In addition, we found that two important downstream target genes of estrogen and heregulin-beta1 that are regulated through E2F-1, cyclin E and NPAT, were both regulated in a similar fashion by all-trans retinoic acid, and these effects were antagonized by dominant-negative HES-1. These findings establish that HES-1 inhibits both estrogen- and heregulin-beta1-stimulated growth of breast cancer cells, and further suggest that growth inhibition induced in these cells by all-trans retinoic acid occurs via HES-1-mediated downregulation of E2F-1 expression.
Insights
All-trans retinoic acid inhibits breast cancer cell growth by downregulating E2F-1 expression via the transcription factor HES-1. This mechanism affects key cell cycle genes, impacting estrogen and heregulin signaling pathways.
Area of Science:
- Molecular Biology
- Cell Biology
- Cancer Research
Background:
- The transcription factor HES-1 is crucial for the growth-inhibitory effects of all-trans retinoic acid (ATRA) in breast cancer cells.
- Estrogen and heregulin-beta1 are known to stimulate breast cancer cell proliferation.
Purpose of the Study:
- To investigate the role of HES-1 in mediating the effects of ATRA on estrogen- and heregulin-beta1-stimulated breast cancer cell growth.
- To elucidate the molecular mechanisms by which HES-1 regulates E2F-1 expression and downstream targets.
Main Methods:
- Utilized T47D breast cancer cells with tetracycline-regulated expression of HES-1 (wild-type and dominant-negative).
- Assessed cell cycle progression (G1/S transition) and Cdk2 activation.
- Quantified E2F-1, cyclin E, and NPAT expression following treatment with ATRA, estrogen, or heregulin-beta1.
- Performed promoter analysis to identify HES-1 binding sites.
Main Results:
- HES-1 expression inhibited G1/S transition and estrogen-induced Cdk2 activation.
- ATRA treatment downregulated estrogen- and heregulin-beta1-induced E2F-1 expression, an effect mediated by HES-1.
- HES-1 directly repressed E2F-1 transcription via a CACGAG-site in the E2F-1 promoter.
- ATRA inhibited heregulin-beta1-stimulated proliferation via HES-1.
- Downstream targets of E2F-1, cyclin E and NPAT, were similarly regulated by ATRA and antagonized by dominant-negative HES-1.
Conclusions:
- HES-1 plays a critical role in inhibiting both estrogen- and heregulin-beta1-stimulated breast cancer cell growth.
- ATRA induces growth inhibition in these cells through HES-1-mediated downregulation of E2F-1 expression.
- The HES-1/E2F-1 pathway represents a key mechanism in breast cancer cell proliferation and a potential therapeutic target.
Related Concept Videos
Cell Specific Gene Expression
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Mitogens and the Cell Cycle
Regulation of the Unfolded Protein Response
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Maintenance of the ES Cell State

